Nuvalent Inc.
Nuvalent Reports $1.4 Billion Cash and Outlines 2026 Milestones
Summary
Nuvalent, Inc. reported approximately $1.4 billion in cash, cash equivalents, and marketable securities as of December 31, 2025, which is expected to fund operations into 2029. The company outlined its 2026 milestones under its 'OnTarget 2026' operating plan, including the FDA acceptance of its NDA for zidesamtinib for ROS1-positive NSCLC, planned NDA submission for neladalkib for ALK-positive NSCLC, and potential indication expansion for zidesamtinib in ROS1-positive NSCLC. Nuvalent also highlighted the progress of its clinical trials and disclosed its financial position that supports its commercial and development activities.
Profitelligence Alerts
Get alerts for NUVL
Be first to know when Nuvalent Inc. files with the SEC.
Filing Categories
Advertisement
About Nuvalent Inc.
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for patients with cancer-related resistance mutations and treatment-related adverse effects. By leveraging their expertise in medicinal chemistry and deep understanding of tumor biology, Nuvalent aims to address significant gaps in current cancer therapies, particularly where existing treatments fall short due to resistance mechanisms. The company operates in a highly specialized sector that covers oncology research and development, presenting potential game-changing approaches within the broader pharmaceutical industry. Through its commitment to research and innovation, Nuvalent collaborates with leading research institutions to push the boundaries of what is achievable in cancer treatment. Situated within an ever-evolving market, the company plays a critical role in advancing new oncological solutions that may ultimately improve the quality of life for patients globally. Founded with the mission to transform patient care, Nuvalent's asset offerings are a testament to the progressive strides being made in next-generation cancer therapeutics.
Official SEC Documents
Advertisement